Clinical Data AZ is three for three with COPD hope tozorakimab PharmaphorumAstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.Clinical DataRespiratoryRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum AstraZeneca’s IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings. Clinical DataRespiratoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trump backs psychedelics for mental health in new executive orderNext: The Omnichannel Gap: Building the CRM of the Future for Patient Services Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
